Synthesis of novel protein arginine methyltransferases inhibitor

HONG Wei,WANG Hao

DOI: https://doi.org/10.3969/j.issn.0258-3283.2012.05.018

2012-01-01

Abstract:A novel inhibitor of protein arginine methyltransferases(PRMTs) has been designed and synthesized.The synthetic approach involved a four-step reaction,halogenation,substitution,guanidinylation and deprotection.The product was confirmed by 1HNMR,13CNMR and MS.

What problem does this paper attempt to address?

The Development of Tetrazole Derivatives as Protein Arginine Methyltransferase I (PRMT I) Inhibitors

Yutong Sun,Zhe Wang,Hao Yang,Xuanli Zhu,Han Wu,Lu Ma,Fang Xu,Wei Hong,Hao Wang,Sun,Wang,Yang,Zhu,Wu,Ma,Xu,Hong,Wang

DOI: https://doi.org/10.3390/ijms20153840

IF: 5.6

2019-08-06

International Journal of Molecular Sciences

Abstract:Protein arginine methyltransferase 1 (PRMT1) can catalyze protein arginine methylation by transferring the methyl group from S-adenosyl-L-methionine (SAM) to the guanidyl nitrogen atom of protein arginine, which influences a variety of biological processes. The dysregulation of PRMT1 is involved in a diverse range of diseases, including cancer. Therefore, there is an urgent need to develop novel and potent PRMT1 inhibitors. In the current manuscript, a series of 1-substituted 1H-tetrazole derivatives were designed and synthesized by targeting at the substrate arginine-binding site on PRMT1, and five compounds demonstrated significant inhibitory effects against PRMT1. The most potent PRMT1 inhibitor, compound 9a, displayed non-competitive pattern with respect to either SAM or substrate arginine, and showed the strong selectivity to PRMT1 compared to PRMT5, which belongs to the type II PRMT family. It was observed that the compound 9a inhibited the functions of PRMT1 and relative factors within this pathway, and down-regulated the canonical Wnt/β-catenin signaling pathway. The binding of compound 9a to PRMT1 was carefully analyzed by using molecular dynamic simulations and binding free energy calculations. These studies demonstrate that 9a was a potent PRMT1 inhibitor, which could be used as lead compound for further drug discovery.

biochemistry & molecular biology,chemistry, multidisciplinary
Arginine Methyltransferase 5 (PRMT5) Inhibitors with 3-(1H-benzo[d]imidazol- 2-Yl)anilines Core Identified by Virtual Screening and Biological Evaluation.

Ying Zhang,Kongkai Zhu,Juan Zhang,Jin-He Zhang,Zhiling Song,Xinlei Zhang,Shan-Kui Liu,Cheng-Shi Jiang

DOI: https://doi.org/10.2174/1381612829666230215105046

IF: 3.31

2023-01-01

Current Pharmaceutical Design

Abstract:BACKGROUND:PRMT5 is a major enzyme responsible for the post-translational symmetric demethylation of protein arginine residues, which has been validated as an effective therapeutic target for cancer. Thus, many nucleoside-based PRMT5 inhibitors have been reported in the past year.OBJECTIVE:To discover a novel series of non-nucleoside PRMT5 inhibitors through a molecular docking-based virtual screening approach.METHODS:Our in-house compound library was virtually screened using the Glide program, identifying a new PRMT5 inhibitor 1. Based on the structural similarity of hit 1, a series of structure-oriented derivatives, including 3a-3e, 7a-7g, and 12a-12f, were synthesized and selected for the inhibitory activity evaluation against PRMT5, as well as cytotoxicity against MV4-11 cell.RESULTS:The analogs 7a-7e with benzimidazole core exhibited potent PRMT5 inhibitory activities, with 7e displaying the most potent activity with an IC50 of 6.81 ± 0.12 μM. In the anti-proliferative assay, compound 7e showed a strong inhibitory effect on MV4-11 cell growth. Finally, the binding mode of 7e with PRMT5 was predicted to provide insights for further structural optimization.CONCLUSION:The newly discovered PRMT5 inhibitors have potential antitumor activity against MV4-11 cells. This work highlighted this series of 3-(1H-benzo[d]imidazol-2-yl)aniline derivatives as novel anti-cancer lead compounds targeting PRMT5, which were worthy of further investigation.
Intralobar pulmonary sequestration: aortographic demonstration.

E. Rubin,M. Rubin,L. Attai,W. G. Heimann

DOI: https://doi.org/10.1378/CHEST.50.6.561

1966-12-01

Diseases of the Chest

Abstract:Two cases of intralobar pulmonary sequestration are reported in which the pre-operative diagnosis was aided by selective aortography. In one, congenital esophagobronchial fistula was also present, the communication with the pulmonary sequestration being demonstrated preoperatively. The literature reveals seven of a total of more than 150 surgically treated patients with intrapulmonary sequestration in whom aortography was useful in the preoperative demonstration of an anomalous blood supply characterizing this type of malformation. The coexistence of congenital esophagobronchial fistula and pulmonary sequestration has been previously reported in four cases. There is reason to believe that pulmonary sequestration, whether intralobar or appearing as an accessory lung (extra-lobar sequestration) is due to disturbances in the normal cycle of embryogenesis.
Pharmacophore-based virtual screening and biological evaluation of small molecule inhibitors for protein arginine methylation

Juxian Wang,Limin Chen,Sarmistha Halder Sinha,Zhongjie Liang,Huifang Chai,Sakthivel Muniyan,Yu-Wei Chou,Chao Yang,Leilei Yan,You Feng,Keqin Kathy Li,Ming-Fong Lin,Hualiang Jiang,Yujun George Zheng,Cheng Luo

DOI: https://doi.org/10.1021/jm300521m

2012-09-27

Abstract:Protein arginine methyltransferases (PRMTs) are proved to play vital roles in chromatin remodeling, RNA metabolism, and signal transduction. Aberrant regulation of PRMT activity is associated with various pathological states such as cancer and cardiovascular disorders. Development and application of small molecule PRMT inhibitors will provide new avenues for therapeutic discovery. The combination of pharmacophore-based virtual screening methods with radioactive methylation assays provided six hits identified as inhibitors against the predominant arginine methyltransferase PRMT1 within micromolar potency. Two potent compounds, A9 and A36, exhibited the inhibitory effect by directly targeting substrate H4 other than PRMT1 and displayed even higher inhibition activity than the well-known PRMT inhibitors AMI-1. A9 significantly inhibits proliferation of castrate-resistant prostate cancer cells. Together, A9 may be a potential inhibitor against advanced hormone-independent cancers, and the work will provide clues for the future development of specific compounds that block the interaction of PRMTs with their targets.
An Adenosine Analogue Library Reveals Insights into Active Sites of Protein Arginine Methyltransferases and Enables the Discovery of a Selective PRMT4 Inhibitor

Youchao Deng,Eui-Jun Kim,Xiaosheng Song,Akshay S. Kulkarni,Ryan X. Zhu,Yidan Wang,Michelle Bush,Aiping Dong,Nicholas Noinaj,Jinrong Min,Wei Xu,Rong Huang

DOI: https://doi.org/10.1021/acs.jmedchem.4c01041

IF: 8.039

2024-10-04

Journal of Medicinal Chemistry

Abstract:Protein arginine methyltransferases (PRMTs) represent promising drug targets. However, the lack of isoform-selective chemical probes poses a significant hurdle in deciphering their biological roles. To address this issue, we devised a library of 100 diverse adenosine analogues, enabling a detailed exploration of the active site of PRMTs. Despite their close homology, our analysis unveiled specific chemical trends unique to the individual members. Notably, compound YD1130 demonstrated over...

chemistry, medicinal
Discovery of novel PRMT5 inhibitors bearing a methylpiperazinyl moiety.

Yuxin Yin,Z. Zhai,Xuyang Zhao,Xinyu Bai,Yan Jin,Ling Liang,Ridong Li

DOI: https://doi.org/10.4155/fmc-2021-0244

2022-06-24

Future Medicinal Chemistry

Abstract:Background: PRMT5 is an epigenetics-related enzyme, which plays a critical role in cancer development. Hence PRMT5 inhibition has been validated as a promising therapeutic strategy. Methods & Results: We synthesized a series of methylpiperazinyl derivatives as novel PRMT5 inhibitors that were achieved by scaffold-hopping from EPZ015666 by virtual screening followed by rational drug design. Among all compounds 43g, bearing a thiourea linker, showed antitumor activity across multiple cancer cell lines and reduced the level of symmetric arginine dimethylation of SmD3 dose-dependently. Moreover, 43g selectively inhibited PRMT5 among protein arginine methyltransferase isoforms. Further proteomics analysis revealed that 43g remarkably reduced the global arginine dimethylation level in a cellular context. Conclusion: This work provides new chemical templates for future structural optimization of PRMT5-related cancer treatments.

Chemistry,Medicine
Design, Synthesis and Biological Evaluation of Novel and Potent Protein Arginine Methyltransferases 5 Inhibitors for Cancer Therapy

Yixuan Tang,Shihui Huang,Xingxing Chen,Junzhang Huang,Qianwen Lin,Lei Huang,Shuping Wang,Qihua Zhu,Yungen Xu,Yi Zou

DOI: https://doi.org/10.3390/molecules27196637

IF: 4.6

2022-10-07

Molecules

Abstract:Protein arginine methyltransferases 5 (PRMT5) is a clinically promising epigenetic target that is upregulated in a variety of tumors. Currently, there are several PRMT5 inhibitors under preclinical or clinical development, however the established clinical inhibitors show favorable toxicity. Thus, it remains an unmet need to discover novel and structurally diverse PRMT5 inhibitors with characterized therapeutic utility. Herein, a series of tetrahydroisoquinoline (THIQ) derivatives were designed and synthesized as PRMT5 inhibitors using GSK-3326595 as the lead compound. Among them, compound 20 (IC50: 4.2 nM) exhibits more potent PRMT5 inhibitory activity than GSK-3326595 (IC50: 9.2 nM). In addition, compound 20 shows high anti-proliferative effects on MV-4-11 and MDA-MB-468 tumor cells and low cytotoxicity on AML-12 hepatocytes. Furthermore, compound 20 possesses acceptable pharmacokinetic profiles and displays considerable in vivo antitumor efficacy in a MV-4-11 xenograft model. Taken together, compound 20 is an antitumor compound worthy of further study.

chemistry, multidisciplinary,biochemistry & molecular biology
Development of an AlphaLISA High Throughput Technique to Screen for Small Molecule Inhibitors Targeting Protein Arginine Methyltransferases

Lakshmi Prabhu,Lan Chen,Han Wei,Ozlem Demir,Ahmad Safa,Lifan Zeng,Rommie E. Amaro,Bert H. O'Neil,Zhon-Yin Zhang,Tao Lu

DOI: https://doi.org/10.1039/c7mb00391a

2017-01-01

Abstract:The protein arginine methyltransferase (PRMT) family of enzymes comprises nine family members in mammals. They catalyze arginine methylation, either monomethylation or symmetric/asymmetric dimethylation of histone and non-histone proteins. PRMT methylation of its substrate proteins modulates cellular processes such as signal transduction, transcription, and mRNA splicing. Recent studies have linked overexpression of PRMT5, a member of the PRMT superfamily, to oncogenesis, making it a potential target for cancer therapy. In this study, we developed a highly sensitive (Z' score = 0.7) robotic high throughput screening (HTS) platform to discover small molecule inhibitors of PRMT5 by adapting the AlphaLISA™ technology. Using biotinylated histone H4 as a substrate, and S-adenosyl-l-methionine as a methyl donor, PRMT5 symmetrically dimethylated H4 at arginine (R) 3. Highly specific acceptor beads for symmetrically dimethylated H4R3 and streptavidin-coated donor beads bound the substrate, emitting a signal that is proportional to the methyltransferase activity. Using this powerful approach, we identified specific PRMT5 inhibitors P1608K04 and P1618J22, and further validated their efficacy and specificity for inhibiting PRMT5. Importantly, these two compounds exhibited much more potent efficacy than the commercial PRMT5 inhibitor EPZ015666 in both pancreatic and colorectal cancer cells. Overall, our work highlights a novel, powerful, and sensitive approach to identify specific PRMT5 inhibitors. The general principle of this HTS screening method can not only be applied to PRMT5 and the PRMT superfamily, but may also be extended to other epigenetic targets. This approach allows us to identify compounds that inhibit the activity of their respective targets, and screening hits like P1608K04 and P1618J22 may serve as the basis for novel drug development to treat cancer and/or other diseases.
Structure, Function, and Activity of Small Molecule and Peptide Inhibitors of Protein Arginine Methyltransferase 1

Thordur Hendrickson-Rebizant,Sadhana R. N. Sudhakar,Michael J. Rowley,Adam Frankel,James R. Davie,Ted M. Lakowski

DOI: https://doi.org/10.1021/acs.jmedchem.4c00490

IF: 8.039

2024-09-10

Journal of Medicinal Chemistry

Abstract:Protein arginine N-methyltransferases (PRMT) are a family of S-adenosyl-l-methionine (SAM)-dependent enzymes that transfer methyl-groups to the ω-N of arginyl residues in proteins. PRMTs are involved in regulating gene expression, RNA splicing, and other activities. PRMT1 is responsible for most cellular arginine methylation, and its dysregulation is involved in many cancers. Accordingly, many groups have targeted PRMT1 using small molecules and peptide inhibitors. In this Perspective, we...

chemistry, medicinal
Prodrug Approach to Exploit (S) Alanine as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors

Ciro Milite,Giuliana Sarno,Ida Pacilio,Agostino Cianciulli,Monica Viviano,Giulia Iannelli,Erica Gazzillo,Alessandra Feoli,Alessandra Cipriano,Maria Giovanna Chini,Sabrina Castellano,Giuseppe Bifulco,Gianluca Sbardella

DOI: https://doi.org/10.1002/cmdc.202400139

IF: 3.54

2024-05-18

ChemMedChem

Abstract:Protein arginine methyltransferase (PRMT) 4 (also known as coactivator‐associated arginine methyltransferase 1; CARM1) is involved in a variety of biological processes and is considered as an emerging target class in oncology and other diseases. A successful strategy to identify PRMT substrate‐competitive inhibitors has been to exploit chemical scaffolds able to mimic the arginine substrate. (S)‐Alanine amide moiety is a valuable arginine mimic for the development of potent and selective PRMT4 inhibitors; however, its high hydrophilicity led to derivatives with poor cellular outcomes. Here, we describe the development of PRMT4 inhibitors featuring a central pyrrole core and an alanine amide moiety. Rounds of optimization, aimed to increase lipophilicity and simultaneously preserve the inhibitory activity, produced derivatives that, despite good potency and physicochemical properties, did not achieve on‐target effects in cells. On the other hand, masking the amino group with a NAD(P)H:quinone oxidoreductase 1 (NQO1)‐responsive trigger group, led to prodrugs able to reduce arginine dimethylation of the PRMT4 substrates BRG1‐associated factor 155 (BAF155). These results indicate that prodrug strategies can be successfully applied to alanine‐amide containing PRMT4 inhibitors and provide an option to enable such compounds to achieve sufficiently high exposures in vivo.

pharmacology & pharmacy,chemistry, medicinal
Labeling Substrates of Protein Arginine Methyltransferase with Engineered Enzymes and Matched S-Adenosyl-L-Methionine Analogues

Rui Wang,Weihong Zheng,Haiqiang Yu,Haiteng Deng,Minkui Luo

DOI: https://doi.org/10.1021/ja2006719

IF: 15

2011-01-01

Journal of the American Chemical Society

Abstract:Elucidating physiological and pathogenic functions of protein methyltransferases (PMTs) relies on knowing their substrate profiles. S-adenosyl-L-methionine (SAM) is the sole methyl-donor cofactor of PMTs. Recently, SAM analogues have emerged as novel small-molecule tools to efficiently label PMT substrates. Here we reported the development of a clickable SAM analogue cofactor, 4-propargyloxy-but-2-enyl SAM, and its implementation to label substrates of human protein arginine methyltransferase 1 (PRMT1). In the system, the SAM analogue cofactor, coupled with matched PRMT1 mutants rather than native PRMT1, was shown to label PRMT1 substrates. The transferable 4-propargyloxy-but-2-enyl moiety of the SAM analogue further allowed corresponding modified substrates to be characterized through a subsequent click chemical ligation with an azido-based probe. The SAM analogue, in combination with a rational protein-engineering approach, thus shows potential to label and identify PMT targets in the context of a complex cellular mixture.
Inhibitory Study of Protein Arginine Methyltransferase 1 Using a Fluorescent Approach.

You Feng,Nan Xie,Jiang Wu,Chao Yang,Yujun George Zheng

DOI: https://doi.org/10.1016/j.bbrc.2008.12.119

IF: 3.1

2009-01-01

Biochemical and Biophysical Research Communications

Abstract:Protein arginine methyltransferases (PRMTs) play important roles in both normal physiology and human diseases. Deregulation of PRMT activity has been linked to several pathological states such as cancer and cardiovascular disorders. Herein, we report our work of designing and using new fluorescent reporters to perform single-step analysis of substrate binding and methylation by PRMT1. Both fluorescence intensity and anisotropy of the two reporters, R4-FL and H4-FL, were shown to effectively manifest enzyme-substrate interactions, highlighting their application in investigating PRMT inhibitors. In particular, the methylation process of R4-FL can be directly studied using fluorescence intensity readout. By combining the fluorescent measurement with radioactive analysis, we determined that AMI-1 inhibits PRMT1 activity through the mechanism of blocking peptide substrate binding.
Acute upregulation of interleukin-1 receptor by ligand.

S. Grenfell,N. Smithers,R. Solari

DOI: https://doi.org/10.1016/1043-4666(92)90046-T

IF: 3.926

1992-03-01

Cytokine

Abstract:
Theoretical insights into catalytic mechanism of protein arginine methyltransferase 1

Ruihan Zhang,Xin Li,Zhongjie Liang,Kongkai Zhu,Junyan Lu,Xiangqian Kong,Sisheng Ouyang,Lin Li,Yujun George Zheng,Cheng Luo

DOI: https://doi.org/10.1371/journal.pone.0072424

IF: 3.7

2013-08-20

PLoS ONE

Abstract:Protein arginine methyltransferase 1 (PRMT1), the major arginine asymmetric dimethylation enzyme in mammals, is emerging as a potential drug target for cancer and cardiovascular disease. Understanding the catalytic mechanism of PRMT1 will facilitate inhibitor design. However, detailed mechanisms of the methyl transfer process and substrate deprotonation of PRMT1 remain unclear. In this study, we present a theoretical study on PRMT1 catalyzed arginine dimethylation by employing molecular dynamics (MD) simulation and quantum mechanics/molecular mechanics (QM/MM) calculation. Ternary complex models, composed of PRMT1, peptide substrate, and S-adenosyl-methionine (AdoMet) as cofactor, were constructed and verified by 30-ns MD simulation. The snapshots selected from the MD trajectory were applied for the QM/MM calculation. The typical SN2-favored transition states of the first and second methyl transfers were identified from the potential energy profile. Deprotonation of substrate arginine occurs immediately after methyl transfer, and the carboxylate group of E144 acts as proton acceptor. Furthermore, natural bond orbital analysis and electrostatic potential calculation showed that E144 facilitates the charge redistribution during the reaction and reduces the energy barrier. In this study, we propose the detailed mechanism of PRMT1-catalyzed asymmetric dimethylation, which increases insight on the small-molecule effectors design, and enables further investigations into the physiological function of this family.
Discovery of a Dual PRMT5–PRMT7 Inhibitor

David Smil,Mohammad S. Eram,Fengling Li,Steven Kennedy,Magdalena M. Szewczyk,Peter J. Brown,Dalia Barsyte-Lovejoy,Cheryl H. Arrowsmith,Masoud Vedadi,Matthieu Schapira

DOI: https://doi.org/10.1021/ml500467h

2015-03-05

ACS Medicinal Chemistry Letters

Abstract:The protein arginine methyltransferases PRMT7 and PRMT5, respectively, monomethylate and symmetrically dimethylate arginine side-chains of proteins involved in diverse cellular mechanisms, including chromatin-mediated control of gene transcription, splicing, and the RAS to ERK transduction cascade. It is believed that PRMT5 and PRMT7 act in conjunction to methylate their substrates, and genetic deletions support the notion that these enzymes derepress cell proliferation and migration in cancer. Using available structures of PRMT5, we designed DS-437, a PRMT5 inhibitor with an IC50 value of 6 μM against both PRMT5 and PRMT7 that is inactive against 29 other human protein-, DNA-, and RNA-methyltransferases and inhibits symmetrical dimethylation of PRMT5 substrates in cells. This compound behaves as a cofactor competitor and represents a valid scaffold to interrogate the potential of the PRMT5-PRMT7 axis as a target for therapy.

chemistry, medicinal
Medicinal chemistry insights into PRMT5 inhibitors

Zhihao Jiao,Yongmi Huang,Kexin Gong,Yiru Liu,Jinxiao Sun,Shangzhe Yu,Guisen Zhao

DOI: https://doi.org/10.1016/j.bioorg.2024.107859

Abstract:Protein arginine methyltransferase 5 (PRMT5) is a type II PRMT enzyme that plays an important role in protein formation. PRMT5 is widely distributed in the nucleus and is involved in regulating a variety of biological processes, including gene transcription, signaling, and cell proliferation. PRMT5 regulates the function and stability of histones through methylation, affecting important cellular activities such as cell cycle regulation, DNA repair, and RNA processing. Studies have shown that PRMT5 is overexpressed in a variety of tumors and is closely related to the occurrence and development of tumors. In recent years, several PRMT5 inhibitors have entered clinical trials for the treatment of various cancers. In view of their importance, this paper reviews the first generation of PRMT5 inhibitors obtained by high-throughput screening, virtual screening, lead compound optimization and substitution modification, as well as novel PRMT5 inhibitors obtained by PROTAC technology and by synthetic lethal principle. Finally, by comparing the differences between the first generation and the second generation, the challenges and future development directions of PRMT5 inhibitors are discussed.
In silico analysis of marine natural product for protein arginine methyltransferase 5(PRMT5) inhibitors based on pharmacophore and molecular docking

Lianxiang Luo,Huiting Tan,Yinglin Liao

DOI: https://doi.org/10.1080/07391102.2023.2184172

2023-03-02

Journal of Biomolecular Structure and Dynamics

Abstract:Over the past few decades, various inhibitors of PRMT5 have been developed because of its involvement in a variety of tumor development processes. As of now, no drugs targeting PRMT5 have been approved, and multiple drugs entering clinical trials have proven to have side effects. In this study, PRMT5 was used to perform virtual screening of 52119 marine natural compounds by combining various methods. We constructed 20 pharmacophore models based on multiple ligands. The best pharmacophore model AARR_2 was selected by analyzing the statistical parameters of the pharmacophore model and the binding characteristics of the ligand active site, and then 3552 compounds were screened out. Compared with the positive compound, 46 compounds were selected based on the molecular docking fraction and docking mode analysis. Then, 3D-QSAR was used to analyze the relationship between structure and activity of the compounds. Then, in addition to marine compounds 36404, 36405 and 14436, we selected compound 46 (the positive control compound) and used the CLC-Pred online Web server to predict their cytotoxicity to human cell lines, making cell experiments possible. Finally, we conducted the prediction of ADMET in order to better promote clinical trials. After comprehensive judgment, we screened out the marine natural compounds 36404 and 36405 as candidates for PRMT5 substrate competitive inhibitors. Communicated by Ramaswamy H. Sarma

English Else
[Minimal residual disease in acute leukemias. Optimal method of detection].

A. Deptała,Z. Kuratowska

1996-06-01

Abstract:
Structure-activity relationship study of a series of nucleoside derivatives bearing sulfonamide scaffold as potent and selective PRMT5 inhibitors

Yuting Chen,Qiongyu Shi,Hong Yang,Jiayi Li,Kaixin Zhou,Junjie Zhang,Zekun Wang,Huanyu Shi,Bing Xiong,Jia Liu,Xun Huang,Tongchao Liu

DOI: https://doi.org/10.1016/j.bioorg.2022.106228

IF: 5.307

2023-01-01

Bioorganic Chemistry

Abstract:Protein arginine methyltransferase 5 (PRMT5) is a promising target for the treatment of malignant tumors. The discovery of nucleoside-derived inhibitors against PRMT5 with novel scaffold has been challenging. Herein, we report our effort on the design and synthesis of nucleoside derivatives bearing sulfonamide scaffold as potent PRMT5 inhibitors. The representative compound 23n was identified as a potent and selective PRMT5 inhibitor with an IC<sub>50</sub> value of 8 nM. Molecular docking study demonstrated the binding mode of compound 23n and illustrated its inhibitory activity to PRMT5. The Trimethyl Lock prodrug strategy was used to afford prodrug 36 with lower polarity which could rapidly release the active compound 23n after entering the tumor cells. Cell-based assays revealed that the prodrug 36 restrained the proliferation of Z-138 and MOLM-13 cells and suppressed methylation of PRMT5 substrate more potently than 23n. Additionally, both compound 23n and 36 exerted antiproliferative effects against Z-138 cells mainly by inducing apoptosis effectively rather than arresting cell cycle. Thus, compounds 23n and 36 represent a series of potent PRMT5 inhibitor with novel scaffold.

biochemistry & molecular biology,chemistry, organic
Discovery of a First-in-Class Inhibitor of the PRMT5-Substrate Adaptor Interaction.

Adam Skepner,A. Ianari,M. Drysdale,M. Mesleh,D. McKinney,W. Sellers,D. Timm,Arthur J. Campbell,Zachary Mullin-Bernstein,P. McCarren,Ritu Singh,M. O’Keefe,Brian J McMillan,B. Bajrami,Jamie A. Moroco,Robert Hilgraf,V. Kaushik,M. Ranaghan,M. Brousseau,D. Porter,F. Wagner,K. Mulvaney,Foxy P. Robinson

DOI: https://doi.org/10.1021/acs.jmedchem.1c00507

IF: 8.039

2021-08-03

Journal of Medicinal Chemistry

Abstract:PRMT5 and its substrate adaptor proteins (SAPs), pICln and Riok1, are synthetic lethal dependencies in MTAP-deleted cancer cells. SAPs share a conserved PRMT5 binding motif (PBM) which mediates binding to a surface of PRMT5 distal to the catalytic site. This interaction is required for methylation of several PRMT5 substrates, including histone and spliceosome complexes. We screened for small molecule inhibitors of the PRMT5-PBM interaction and validated a compound series which binds to the PRMT5-PBM interface and directly inhibits binding of SAPs. Mode of action studies revealed the formation of a covalent bond between a halogenated pyridazinone group and cysteine 278 of PRMT5. Optimization of the starting hit produced a lead compound, BRD0639, which engages the target in cells, disrupts PRMT5-RIOK1 complexes, and reduces substrate methylation. BRD0639 is a first-in-class PBM-competitive inhibitor that can support studies of PBM-dependent PRMT5 activities and the development of novel PRMT5 inhibitors that selectively target these functions.

Chemistry,Medicine

Synthesis of novel protein arginine methyltransferases inhibitor

The Development of Tetrazole Derivatives as Protein Arginine Methyltransferase I (PRMT I) Inhibitors

Arginine Methyltransferase 5 (PRMT5) Inhibitors with 3-(1H-benzo[d]imidazol- 2-Yl)anilines Core Identified by Virtual Screening and Biological Evaluation.

Intralobar pulmonary sequestration: aortographic demonstration.

Pharmacophore-based virtual screening and biological evaluation of small molecule inhibitors for protein arginine methylation

An Adenosine Analogue Library Reveals Insights into Active Sites of Protein Arginine Methyltransferases and Enables the Discovery of a Selective PRMT4 Inhibitor

Discovery of novel PRMT5 inhibitors bearing a methylpiperazinyl moiety.

Design, Synthesis and Biological Evaluation of Novel and Potent Protein Arginine Methyltransferases 5 Inhibitors for Cancer Therapy

Development of an AlphaLISA High Throughput Technique to Screen for Small Molecule Inhibitors Targeting Protein Arginine Methyltransferases

Structure, Function, and Activity of Small Molecule and Peptide Inhibitors of Protein Arginine Methyltransferase 1

Prodrug Approach to Exploit (S) Alanine as Arginine Mimic Moiety in the Development of Protein Arginine Methyltransferase 4 Inhibitors

Labeling Substrates of Protein Arginine Methyltransferase with Engineered Enzymes and Matched S-Adenosyl-L-Methionine Analogues

Inhibitory Study of Protein Arginine Methyltransferase 1 Using a Fluorescent Approach.

Acute upregulation of interleukin-1 receptor by ligand.

Theoretical insights into catalytic mechanism of protein arginine methyltransferase 1

Discovery of a Dual PRMT5–PRMT7 Inhibitor

Medicinal chemistry insights into PRMT5 inhibitors

In silico analysis of marine natural product for protein arginine methyltransferase 5(PRMT5) inhibitors based on pharmacophore and molecular docking

[Minimal residual disease in acute leukemias. Optimal method of detection].

Structure-activity relationship study of a series of nucleoside derivatives bearing sulfonamide scaffold as potent and selective PRMT5 inhibitors

Discovery of a First-in-Class Inhibitor of the PRMT5-Substrate Adaptor Interaction.